# A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

> **NCT02324257** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 149 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RO6958688
- **DRUG:** Obinutuzumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02324257
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-30
- **Primary completion:** 2019-09-03
- **Final completion:** 2019-09-03
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2020-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324257, "A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02324257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*